Lancet: Oxford University: AstraZeneca + Pfizer, is there a "miracle effect" in the mixed use of the new crown vaccine?

The new crown epidemic has been raging around the world for one and a half years.
The new crown vaccine has become an effective way for everyone to prevent the virus from invading.
Whether vaccines can be mixed has also become a topic of concern
.

A variety of vaccines have been on the market, the German Chancellor personally went to battle to accept the vaccine mix

A variety of vaccines have been on the market, the German Chancellor personally went to battle to accept the vaccine mix

Data from Our World in Data shows that today, 16 vaccines have been marketed worldwide and authorized to be used in different countries, and 322 vaccines are in research, 99 of which have entered clinical trials
.

Among the 16 vaccines on the market, their types are mainly divided into mRNA vaccines, adenovirus vector vaccines, new coronavirus inactivated vaccines and recombinant protein vaccines

In China, it is mainly recognized that vaccines from different manufacturers but belong to the same type are used for mixed injection of the first and second injections, while Canada, Germany and other European and American countries advocate the mixed use of different types of vaccines.
This has also become a question for everyone.
, Can the safety of mixed vaccines be guaranteed
? In order for everyone to dispel doubts, German Chancellor Merkel even went to battle personally.

After receiving the first shot of the Oxford-AstraZeneca adenovirus vector new crown vaccine, the second shot chose Pfizer-BioNTech's mRNA new crown vaccine

A number of studies have focused on the mixed use of vaccines, the effect is even stronger than the same type of injection?

A number of studies have focused on the mixed use of vaccines, the effect is even stronger than the same type of injection?

Recently, the Oxford University Vaccine Research and Development Group released the latest research results on the mixed use of the new crown vaccine in the "Lancet" preprint.
The title of the article is " Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine ", the study pointed out that when the vaccination interval is four weeks, alternating injections of AstraZeneca's new crown vaccine and Pfizer's new crown vaccine can make antibodies against the new crown virus S protein The ability of the body will be enhanced, so that the body produces a stronger immune barrier
.

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

https://doi.
org/10.
2139/ssrn.
3874014

https://doi.
org/10.
2139/ssrn.
3874014 https://doi.
org/10.
2139/ssrn.
3874014

The study was launched in February this year.
A total of 830 people participated.
The average age is 57.
8 years, 45.
8% are women, and 25.
8% are ethnic minorities.
The trial uses AstraZeneca (ChAd) and Pfizer (BNT) new crown vaccines.
The subjects were divided into 8 groups.
The 8 groups will receive the vaccine injection procedures of ChAd/ChAd, ChAd/BNT, BNT/BNT, and BNT/ChAd.
The interval between the two injections is controlled at 28 days and 84 days, respectively
.

The test results show that when the injection interval between two injections is 28 days, the geometric mean antibody titer of ChAd/BNT group vaccinators is better than that of ChAd/ChAd group vaccinators.
At the same time, the geometric mean value of T cell responses is also higher than that of other groups.
Much higher, this result is especially obvious when comparing standard injections of the same type
.

This shows that compared with other injection procedures, the first injection of AstraZeneca vaccine and the second injection of Pfizer vaccine will stimulate the immune response of antibodies and T cells in the human body more than the standard injection of the same type of vaccine

In fact, the results of this study were released as early as May of this year, but the results at that time showed that the frequency of transient mild to moderate adverse reactions in the mixed vaccination population showed an upward trend
.

The first proposal that mixed vaccines can improve the human body’s resistance to the new coronavirus came from the Carlos III Health Research Institute of Spain.

Safety issues are still the top priority of new crown vaccine mixed use

Safety issues are still the top priority of new crown vaccine mixed use

At present, there is no clinical trial report that the mixed use of the new crown vaccine can produce serious side effects.
However, each vaccine has its own side effects and adverse reactions.
Take AstraZeneca's new crown vaccine as an example.
There are many reports of thrombosis and even death after vaccination with AstraZeneca, so that many countries have suspended vaccination of the company's vaccine.
Therefore, mixed vaccination of two different types of vaccines is still risky
.

At present, the number of vaccination in the world has exceeded 3 billion, and clinical research on the mixed use of vaccines is only limited to a few hundred people
.

According to current estimates, after the first injection of the Oxford-AstraZeneca vaccine, approximately 1 in 50,000 people will have a blood clot, and after the second injection, 1 in less than 1.

Now, a number of studies on the mixed use of new crown vaccines have begun
.

In April of this year, the Oxford University's new crown vaccine mixed clinical trial added two new vaccine products, Moderna and Novavax.

Original source:

Original source:

Xinxue Liu, et al.

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine.
Leave a message here